// App-Quantinova.ai

: Real-world assessment of AR-LBD mutations in metastatic castration-resistant prostate cancer.

Researchers

Presenter

  • Emmanuel S. Antonarakis

Principal Investigators

  • Nicole Zhang

  • Jayati Saha

  • Liina Nevalaita

  • Scott A. Shell

  • Chris Garratt

  • Tarja Ikonen

  • Karim Fizazi

Medical Centers

  • Orion Pharma, Nottingham, United Kingdom

  • Orion Corporation Orion Pharma, Turku and Espoo, Finland

  • Guardant Health, Inc., Palo Alto, CA

  • University of Minnesota Physician's Oncology Clinics, Minneapolis, MN

  • Guardant Health, Rewdwood City, CA

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

Locations

  • France

  • United Kingdom

  • Finland

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating DNA

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved